Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

What are the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have an exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors and a progression-free survival (PFS) of 5 years or longer after starting maintenance PARP inhibitors?In this cohort study of 320 patients with platinum-sensitive recurrent ovarian cancer and an exceptional response to PARP inhibitor use, the 10-year PFS was 78.7%, and patients who stopped taking PARP inhibitors for reasons other than progression did not experience worse PFS (10-year PFS, 90.1%). Late-onset myeloid cancers occurred in 5 patients (1.6%).Patients with exceptional response had favorable long-term outcomes, with prolonged PFS and low rates of myeloid cancers, raising questions regarding the optimal duration of PARP inhibitors and the possibility of functional cure.

Corresponding Author: Michael Friedlander, MBChB(Hons), PhD, Prince of Wales Hospital and the Royal Hospital for Women, Corner of Avoca and High St, Randwick NSW 2031 Australia (m.friedlander@unsw.edu.au).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.